Document is current
Any future updates will be listed below
-
Authors
Brakemeier, S.
Lipka, J.
Schlag, M.
Kleinschnitz, C.
Hagenacker, T. http://orcid.org/0000-0002-3631-3450
-
Funding
Funding for this research was provided by:
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 8 September 2023
Revised: 12 January 2024
Accepted: 16 January 2024
First Online: 15 February 2024
Declarations
:
: S.B. has no conflicts of interest. J.L. has no conflicts of interest. M.S. has no conflicts of interest. C.K. received lecture and consultancy fees from Biogen, Roche, and Novartis. T.H. received lecture and consultancy fees from Biogen, Roche and Novartis, as well as research support from Biogen, Roche, and Novartis Gene Therapies. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the local ethics committee of the University of Duisburg, Essen, Germany (approval number: 18-8071-BO).
: All patients provided written informed consent prior to inclusion in the study.
